TREATMENT OF EXPERIMENTAL PERIODONTITIS BY TERPENE-CONTAINING MEDICATION

Therapeutic effect of terpenoidisobornylacetate-containing preparation Antiran on the inflammatory process in paradontium in 56 white outbread rats was researched. Animals of control group wasn't provide the treatment, animals of treatment group had antibiotic dialysis from 1st till 3rd day, ultrasound curettage with Antiran solution on the 4th day, Antiran dialysis in the paradontium tissues for 20 minutes OD from 5th to 14th day. Inflammatory process was studied using morphological methods. It was showed that Aniran arrests an inflammation, prevents secondary alteration of tissues, promotes reparative processes and recovery of damaged tissues

Clinical estimation of efficiency of application of terpene-containing preparation in complex treatment of chronic generalized parodontitis

The article presents the comparative analysis of application of terpene-containing medicine Antiran (1:3 solution) and 0.06% chlorhexidine bigluconate solution in a complex therapy of patients with chronic generalized parodontitis. According to the curative effect, these drugs are comparable with antibacterial and antiseptic agents, but they act more gently and, as a rule, do not cause side effects. Currently, as a etiotropic therapy of periodontitis, a wide range of drugs affecting the parodontal pathogenic microflora, irrational use of antibacterial agents has acquired the status of a global problem of modern medicine, since it leads to the emergence of resistant strains of microorganisms that are poorly sensitive or resistant to treatment. The medicaments were used in ultrasonic scaling and for passive ultrasonic irrigation of periodontal pockets during curettage process. The results were evaluated according to the PMA, SBI, PI indexes, an extravazation time formation and periodontal pockets depth. The first total time period of clinical observation established that inflammation process was eliminated earlier when Antiran was used. Thus our study demonstrated and substantiated the successful experience of Antiran application in periodontal practice

Этнические аспекты наследственного рака молочной железы

This study aimed to reveal the spectrum of BRca1 and BRca2 genes mutation in various ethnic groups of the Russian Federation. asystematic literature search includes data for the past 10 years and was conducted by using electronic databases of pubmed, eliBRaRY and ect.Material and methods. The review includes research data on the frequency of mutations of breast cancer-associated genes in various ethnic groups of the Russian Federation.Results. For «slavic» patients with a family history, the BRca1/2 mutation testing is the standard of care. in addition, the development of new antitumour drugs has resulted in improved survival rates. more than 1000 mutations of the BRca1 gene have been identified. Recent research is focused on the confirmation the beneficial effect of identified mutations. For the indigenous population (mongoloid ethnic groups), there are no standards for the treatment of inherited breast cancer. thus, the advances in molecular oncology for the treatment of hereditary breast cancer are not available for the indigenous population of the Russian Federation.Conclusion. In this context, the search for markers of early cancer detection and the development of criteria for therapy response are relevant for indigenous people. the development of new predictive and prognostic criteria of breast cancer among mongoloid ethnic groups with a family history will allow the innovative strategies for personalized molecular therapy to be developed.Цель исследования – провести систематический анализ данных, имеющихся в современной литературе, о спектре мутаций генов BRca1 и BRca2 в различных этнических группах Российской Федерации.Материал и методы. В обзор включены данные исследований о частоте встречаемости мутаций РМЖ-ассоциированных генов у различных этнических групп Российской Федерации, опубликованные за последние 10 лет. Поиск производился в системах pubmed, eliBRaRYи др.Результаты. В настоящее время тестирование BRca1/2 мутаций является стандартом в лечении наследственного РМЖ у «славянских» пациентов с семейной историей, достигнут прогресс в разработке новых противоопухолевых препаратов и значительный рост показателей выживаемости, идентифицировано более 1000 мутаций гена BRca1, продолжается поиск патогенных клинически значимых мутаций для данной группы больных. Однако на данный момент отсутствуют сведения о молекулярных факторах, которые обусловливают риск развития наследственных форм РМЖ для коренного населения Российской Федерации (буряты, эвенки, якуты, алтайцы, тувинцы, хакасы и др.). Таким образом, современные достижения молекулярной онкологии в лечении наследственных форм РМЖ не доступны для коренного населения Российской Федерации.Заключение. Представленные данные подтверждают актуальность поиска маркеров ранней диагностики, эффективности терапии, риска прогрессирования РМЖ у коренных этносов. Данные о молекулярных механизмах наследственного РМЖ у этнических групп с семейной историей, принадлежащих к монголоидной расе, позволят в перспективе разработать инновационные стратегии персонализированной молекулярной терапии

Новая мутация в гене PALB2, ассоциированная с наследственным раком молочной железы у молодой пациентки, принадлежащей к якутской этнической группе

Background. Breast cancer (BC) is the most common female malignancy worldwide. Partner And Localizer of BRCA2 gene (PALB2) is directly involved in DNA damage response. Germline mutation in PALB2 has been identified in breast cancer and familial pancreatic cancer cases, accounting for approximately 1–2% and 3–4%, respectively. The goal of this report was to describe new PALB2 mutation in a young Yakut breast cancer patient with family history of cancer. Material and Methods. Genomic DNA were isolated from blood samples and used to prepare libraries using a capture-based target enrichment kit, Hereditary Cancer Solution™ (SOP HiA GE NETICS , Switzerland), covering 27 genes (ATM, APC, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, PMS2CL, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53 and XRCC2). Paired-end sequencing (2 × 150 bp) was conducted using NextSeq 500 system (Illumina, USA ). Results. Here we describe a case of a never-before-reported mutation in the PALB2 gene that led to the early onset breast cancer. We report the case of a 39-year-old breast cancer Yakut woman with a family history of pancreatic cancer. Bioinformatics analysis of the NGS data revealed the presence of the new PALB2 gene germinal frameshift deletion (NM_024675:exon1:c.47delA:p.K16fs). In accordance with dbPubMed ClinVar, new mutation is located in codon of the PALB2 gene, where the likely pathogenic donor splice site mutation (NM_024675.3:c.48+1delG) associated with hereditary cancer-predisposing syndrome has been earlier described. Conclusion. We found a new never-before-reported mutation in PALB2 gene, which probably associated with early onset breast cancer in Yakut indigenous women with a family history of pancreatic cancer.Актуальность. Рак молочной железы занимает лидирующие позиции по уровню заболеваемости во всем мире. Ген онкосупрессор PALB2 наряду с такими генами, как BRCA1, BRCA2, вовлечен в процессы репарации поврежденной ДНК. Частота встречаемости герминальных мутаций гена PALB2 при раке молочной железы и семейных случаях рака поджелудочной железы составляет приблизительно 1–2 % и 3–4 % соответственно. Представлен клинический случай 39-летней женщины, принадлежащей к якутской этнической группе, с диагнозом рак молочной железы с семейной историей рака поджелудочной железы. Материал и методы. Геномная ДНК выделена из периферической крови, ДНК-библиотеки приготавливали с использованием набора Hereditary Cancer Solution™ (Sophia Genetics, Швейцария) для изучения статуса 27 генов (ATM, APC, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, PMS2CL, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53 и XRCC2). Секвенирование (2 × 150 п.н.) проводилось с использованием системы NextSeq 500 (Illumina, США). Результаты. По результатам биоинформатического анализа данных NGS у 39-летней женщины, принадлежащей к якутской этнической группе, с диагнозом рак молочной железы с семейной историей рака поджелудочной железы обнаружена новая герминальная мутация гена PALB2 со сдвигом рамки считывания (NM_024675: Exon1: c.47delA: p.K16FS). В соответствии с dbPubmed ClinVar новая мутация гена PALB2 расположена в том же кодоне, где ранее была описана, вероятно патогенная, мутация сайта сплайсинга (NM_024675.3: Exon1: c.48+1delG), вовлеченная в патогенез наследственных форм рака молочной железы и яичника. Заключение. Впервые у 39-летней женщины, принадлежащей к якутской этнической группе, с диагнозом рак молочной железы и с семейной историей рака поджелудочной железы обнаружена новая, вероятно патогенная, герминальная мутация гена PALB2 со сдвигом рамки считывания (NM_024675: Exon1: c.47delA: p.K16FS)

Spin chemistry investigation of peculiarities of photoinduced electron transfer in donor-acceptor linked system

Photoinduced intramolecular electron transfer in linked systems, (R,S)- and (S,S)-naproxen-N-methylpyrrolidine dyads, has been studied by means of spin chemistry methods [magnetic field effect and chemically induced dynamic nuclear polarization (CIDNP)]. The relative yield of the triplet state of the dyads in different magnetic field has been measured, and dependences of the high-field CIDNP of the N-methylpyrrolidine fragment on solvent polarity have been investigated. However, both (S,S)- and (R,S)-enantiomers demonstrate almost identical CIDNP effects for the entire range of polarity. It has been demonstrated that the main peculiarities of photoprocesses in this linked system are connected with the participation of singlet exciplex alongside with photoinduced intramolecular electron transfer in chromophore excited state quenching.This work was supported by the grants 08-03-00372 and 11-03-01104 of the Russian Foundation for Basic Research, and the grant of Priority Programs of the Russian Academy of Sciences, nr. 5.1.5.Magin, I.; Polyakov, N.; Khramtsova, E.; Kruppa, A.; Stepanov, A.; Purtov, P.; Leshina, T.... (2011). Spin chemistry investigation of peculiarities of photoinduced electron transfer in donor-acceptor linked system. Applied Magnetic Resonance. 41(2-4):205-220. https://doi.org/10.1007/s00723-011-0288-3S205220412-4J.S. Park, E. Karnas, K. Ohkubo, P. Chen, K.M. Kadish, S. Fukuzumi, C.W. Bielawski, T.W. Hudnall, V.M. Lynch, J.L. Sessler, Science 329, 1324–1327 (2010)S.Y. Reece, D.G. Nocera, Annu. Rev. Biochem. 78, 673–699 (2009)M.S. Afanasyeva, M.B. Taraban, P.A. Purtov, T.V. Leshina, C.B. Grissom, J. Am. Chem. Soc. 128, 8651–8658 (2006)M.A. Fox, M. Chanon, in Photoinduced Electron Transfer. C: Photoinduced Electron Transfer Reactions: Organic Substrates (Elsevier, New York, 1988), p. 754P.J. Hayball, R.L. Nation, F. Bochner, Chirality 4, 484–487 (1992)N. Suesa, M.F. Fernandez, M. Gutierrez, M.J. Rufat, E. Rotllan, L. Calvo, D. Mauleon, G. Carganico, Chirality 5, 589–595 (1993)A.M. Evans, J. Clin. Pharmacol. 36, 7–15 (1996)Y. Inoue, T. Wada, S. Asaoka, H. Sato, J.-P. Pete, Chem Commun. 4, 251–259 (2000)T. Yorozu, K. Hayashi, M. Irie, J. Am. Chem. Soc. 103, 5480–5548 (1981)N.J. Turro, in Modern Molecular Photochemistry (Benjamin/Cummings, San Francisco, 1978)K.M. Salikhov, Y.N. Molin, R.Z. Sagdeev, A.L. Buchachenko, in Spin Polarization and Magnetic Field Effects in Radical Reactions (Akademiai Kiado, Budapest, 1984), p. 419E.A. Weiss, M.A. Ratner, M.R. Wasielewski, J. Phys. Chem. A 107, 3639–3647 (2003)A.S. Lukas, P.J. Bushard, E.A. Weiss, M.R. Wasielewski, J. Am. Chem. Soc. 125, 3921–3930 (2003)R. Nakagaki, K. Mutai, M. Hiramatsu, H. Tukada, S. Nakakura, Can. J. Chem. 66, 1989–1996 (1988)M.C. Jim′enez, U. Pischel, M.A. Miranda, J. Photochem. Photobiol. C Photochem. Rev. 8, 128–142 (2007)S. Abad, U. Pischel, M.A. Miranda, Photochem. Photobiol. Sci. 4, 69–74 (2005)U. Pischel, S. Abad, L.R. Domingo, F. Bosca, M.A. Miranda, Angew. Chem. Int. Ed. 42, 2531–2534 (2003)G.L. Closs, R.J. Miller, J. Am. Chem. Soc. 101, 1639–1641 (1979)G.L. Closs, R.J. Miller, J. Am. Chem. Soc. 103, 3586–3588 (1981)M. Goez, Chem. Phys. Lett. 188, 451–456 (1992)I.F. Molokov, Y.P. Tsentalovich, A.V. Yurkovskaya, R.Z. Sagdeev, J. Photochem. Photobiol. A 110, 159–165 (1997)U. Pischel, S. Abad, M.A. Miranda, Chem. Commun. 9, 1088–1089 (2003)H. Hayashi, S. Nagakura, Bull. Chem. Soc. Jpn. 57, 322–328 (1984)Y. Sakaguchi, H. Hayashi, S. Nagakura, Bull. Chem. Soc. Jpn. 53, 39–42 (1980)H. Yonemura, H. Nakamura, T. Matsuo, Chem. Phys. Lett. 155, 157–161 (1989)N. Hata, M. Hokawa, Chem. Lett. 10, 507–510 (1981)M. Shiotani, L. Sjoeqvist, A. Lund, S. Lunell, L. Eriksson, M.B. Huang, J. Phys. Chem. 94, 8081–8090 (1990)E. Schaffner, H. Fischer, J. Phys. Chem. 100, 1657–1665 (1996)Y. Mori, Y. Sakaguchi, H. Hayashi, Chem. Phys. Lett. 286, 446–451 (1998)I.M. Magin, A.I. Kruppa, P.A. Purtov, Chem. Phys. 365, 80–84 (2009)K.K. Barnes, Electrochemical Reactions in Nonaqueous Systems (M. Dekker, New York, 1970), p. 560J. Bargon, J. Am. Chem. Soc. 99, 8350–8351 (1977)M. Goez, I. Frisch, J. Phys. Chem. A 106, 8079–8084 (2002)A.K. Chibisov, Russ. Chem. Rev. 50, 615–629 (1981)J. Goodman, K. Peters, J. Am. Chem. Soc. 107, 1441–1442 (1985)H. Cao, Y. Fujiwara, T. Haino, Y. Fukazawa, C.-H. Tung, Y. Tanimoto, Bull. Chem. Soc. Jpn. 69, 2801–2813 (1996)P.A. Purtov, A.B. Doktorov, Chem. Phys. 178, 47–65 (1993)A.I. Kruppa, O.I. Mikhailovskaya, T.V. Leshina, Chem. Phys. Lett. 147, 65–71 (1988)M.E. Michel-Beyerle, R. Haberkorn, W. Bube, E. Steffens, H. Schröder, H.J. Neusser, E.W. Schlag, H. Seidlitz, Chem. Phys. 17, 139–145 (1976)K. Schulten, H. Staerk, A. Weller, H.-J. Werner, B. Nickel, Z. Phys. Chem. 101, 371–390 (1976)K. Gnadig, K.B. Eisenthal, Chem. Phys. Lett. 46, 339–342 (1977)T. Nishimura, N. Nakashima, N. Mataga, Chem. Phys. Lett. 46, 334–338 (1977)M.G. Kuzmin, I.V. Soboleva, E.V. Dolotova, D.N. Dogadkin, High Eng. Chem. 39, 86–96 (2005

MODERN TRENDS IN MEDICAL THERAPY OF CHRONIC GENERALIZED PARODONTITIS

The review deals with the analysis of modern methods of treatment of chronic generalized parodontitis from the perspective of differentiated principle of treatment of this disease. Particular attention is paid to methods of medical treatment, their diversity on the efficiency and mechanisms of therapeutic effects to select appropriate treatment, taking into account all the individual characteristics of the patient, aetiology, pathogenesis and severity of chronic generalized parodontitis. It has been demonstrated that an important aspect to achieve high efficiency of treatment is a method of drug delivery. The most effective method is a transmembrane dialysis, which makes it possible simultaneously to obtain the maximum concentration of the therapeutic substances in the inflammatory focus and to eliminate from the inflammatory focus the low-medium weight tissue decomposition products, products of metabolism, while maintaining factors of regeneration and protection against infection. It has been evinced the advantages of sanogenetic therapy using vitamin cocktail and some higher plants BAS containing terpenoids (bornylacetate and its semisynthetic stereoisomer - isobornyl acetate), as the least toxic, having analgesic and anti-bacterial properties comparable with antibiotics, and capable to stimulate repair processes. The good water solubility of these substances provides ample possibility of using these drugs in the form of solutions for rinsing, transmembrane dialysis, as liquid at ultrasonic curettage

Ethnic aspects of hereditary breast cancer

This study aimed to reveal the spectrum of BRca1 and BRca2 genes mutation in various ethnic groups of the Russian Federation. asystematic literature search includes data for the past 10 years and was conducted by using electronic databases of pubmed, eliBRaRY and ect.Material and methods. The review includes research data on the frequency of mutations of breast cancer-associated genes in various ethnic groups of the Russian Federation.Results. For «slavic» patients with a family history, the BRca1/2 mutation testing is the standard of care. in addition, the development of new antitumour drugs has resulted in improved survival rates. more than 1000 mutations of the BRca1 gene have been identified. Recent research is focused on the confirmation the beneficial effect of identified mutations. For the indigenous population (mongoloid ethnic groups), there are no standards for the treatment of inherited breast cancer. thus, the advances in molecular oncology for the treatment of hereditary breast cancer are not available for the indigenous population of the Russian Federation.Conclusion. In this context, the search for markers of early cancer detection and the development of criteria for therapy response are relevant for indigenous people. the development of new predictive and prognostic criteria of breast cancer among mongoloid ethnic groups with a family history will allow the innovative strategies for personalized molecular therapy to be developed

New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients

In Russia, more than 50,000 women are diagnosed with breast cancer (BC) every year. Russia is a multinational country — about 200 ethnic groups live on its territory. Khakass, Buryats, Tuvans and other ethnic groups show higher rate of increase in BC incidence and a younger age of first diagnosed BC compared to Caucasian ethnicities. We focused on Tuvan ethnic group to find specific genetic aberrations associated with BC. There are no BC prevention models as well as standards for the treatment of inherited BC in Tuvans. In this context, the search for genetic markers of early cancer detection and the development of criteria for therapy response are relevant. Aim: To identify hereditary mutations in BC-associated genes in Tuvan women. Materials and Methods: 24 patients with early-onset BC (range, 25 to 46 years) were enrolled in the study. Genomic DNA isolated from blood samples was used to prepare libraries using a capture-based target enrichment kit covering 27 genes (ATM, APC, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, PMS2CL, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53 and XRCC2). Next-generation sequencing was performed using the Illumina NextSeq500 System. Results: In our study, one pathogenic mutation was detected in BRCA1 (rs80357868) gene (prevalence of 4%, 1/24). We identified the truncating 3875_3878delGTCT mutation of BRCA1 gene in Tuvans BC patient aged 34 years. We also detected three mutations that were probably damaging by PolyPhen2 and/or deleterious by SIFT in ATM (rs781023264), MUTYH (rs199840380) and RAD51D (rs145309168) genes. Conclusion: To the best of our knowledge, this is the first report that describes the highly pathogenic variant in the BRCA1 gene (rs80357868) and possibly damaging (PolyPhen2) germline variants in the ATM (rs781023264), MUTYH (rs199840380) and RAD51